qingfeng medical group takes r&d as its development strategy and invests no less than 10% of its annual sales in r&d. in shanghai, beijing, hangzhou, ganzhou and other places, we have built collaborative and efficient platforms for chemical innovative drugs, high-value generic drugs platform, cellular immunity platform, innovative natural medicine research platform, pilot transformation platform and the world's largest class a level biomedical innovation professional accelerator. in addition, we have established high-end research and development platforms such as national key laboratories, national enterprise technology centers, national post-doctoral research workstations and academician workstations, forming a global, full-chain innovation and research system, and creating an innovation ecosystem of open cooperation in the pharmaceutical industry.
│shanghai r&d center
r&d headquarters
focusing on innovative biomedicine projects of new anti-tumor monoclonal antibodies and small molecule targeted therapies, we have built a leading research and development pipelines in china. located in shanghai zhangjiang high-tech park, the core area of china's biomedical industry, the platform covers an area of about 3,000 square meters. it has departments of pharmaceutical, biological, pharmaceutical, analytical, pharmaceutical and other departments, as well as advanced equipment for new drug research and development.
chemical pharmaceutical innovation platform
we are committed to the research and development of innovative small molecule drugs that are unmet in clinical need, including the research and development of innovative small molecule drugs targeting the latest targets in anti-tumor, antiviral, immunoregulatory and other related fields.
│hangzhou r&d center
hangzhou r&d center is committed to the small-scale research and preparation development of innovative drugs and high-end generic drugs. the r&d center covers an area of 10,000 square meters, and the experimental platform is designed and built according to the standards of eu gmp, us fda cgmp and chinese gmp.
│ganzhou r&d center
new drugs and technology transfer platform
with standard laboratories, equipped with domestic and foreign advanced instruments and equipment, with drug synthesis, analysis and research, preparation development and pilot research and other innovation platforms, the platform can independently complete new drugs small test, pilot study and technology transfer.
natural medicine innovation platform
state key laboratory of innovative natural medicine and tcm injections: the laboratory is an enterprise state key laboratory approved by the ministry of science and technology in 2015 and one of the first national key laboratories in jiangxi province, aiming at the research and development of innovative natural medicine and the improvement of safety of tcm injections.
│qingfeng clinical & medical business unit
clinical research platforms have been set up in beijing and shanghai, mainly engaging in the clinical trial and application of new drugs, including application and registration, sites selection, sop establishment, project management and quality control, rapid patient enrollment, etc., and a multi-disciplinary clinical research network has been established covering oncology, cardiovascular diseases, nervous system diseases and other fields.